Preferred Label : DORAVIRINE;
Chemical formula : C17H11ClF3N5O3;
UNII : 913P6LK81M;
Origin ID : C000592662;
UMLS CUI : C4045491;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3360844/fr/pifeltro-doravirine-adolescents-ages-de-12-ans-a-moins-de-18-ans-et-pesant-au-moins-35-kg-infectes-par-le-vih-1
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
adolescent
hiv infections
administration, oral
DORAVIRINE
doravirine
reverse transcriptase inhibitors
HIV-1
Non-nucleoside Reverse Transcriptase Inhibitor
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/p_3360847/fr/delstrigo-tenofovir-disoproxil/-doravirine/-lamivudine-vih-adolescents
2022
false
false
false
France
adolescent
drug combinations
treatment outcome
insurance, health, reimbursement
administration, oral
lamivudine, tenofovir disoproxil and doravirine
DORAVIRINE
lamivudine
tenofovir disoproxil fumarate
hiv infections
anti-hiv agents
evaluation of the transparency committee
---
https://www.has-sante.fr/portail/jcms/c_2965623/fr/delstrigo
https://www.has-sante.fr/portail/jcms/c_2965623/fr/delstrigo-doravirine-lamivudine-tenofovir-disoproxil-association-d-antiretroviraux
2019
false
true
false
false
France
French
treatment outcome
Tenofovir Disoproxil
Tenofovir
lamivudine
DORAVIRINE
drug combinations
lamivudine, tenofovir disoproxil and doravirine
adult
hiv infections
anti-hiv agents
administration, oral
reverse transcriptase inhibitors
evaluation of the transparency committee
insurance, health, reimbursement
guidelines for drug use
HIV-1
doravirine
pyridones
triazoles
---
https://www.ema.europa.eu/en/medicines/human/EPAR/pifeltro
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
DORAVIRINE
DORAVIRINE
doravirine
reverse transcriptase inhibitors
reverse transcriptase inhibitors
anti-hiv agents
anti-hiv agents
adult
hiv infections
administration, oral
product surveillance, postmarketing
drug therapy, combination
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
pyridones
triazoles
pyridones
triazoles
---
https://www.ema.europa.eu/en/medicines/human/EPAR/delstrigo
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Tenofovir Disoproxil
Tenofovir
lamivudine
DORAVIRINE
Tenofovir Disoproxil
DORAVIRINE
lamivudine
drug combinations
drug approval
europe
Tenofovir
lamivudine, tenofovir disoproxil and doravirine
adult
hiv infections
anti-hiv agents
anti-hiv agents
administration, oral
reverse transcriptase inhibitors
reverse transcriptase inhibitors
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
pyridones
triazoles
pyridones
triazoles
---
https://www.has-sante.fr/portail/jcms/c_2965620/fr/pifeltro
https://www.has-sante.fr/portail/jcms/c_2965620/fr/pifeltro-doravirine-antiretroviral
2019
false
true
false
false
France
French
treatment outcome
DORAVIRINE
doravirine
reverse transcriptase inhibitors
anti-hiv agents
adult
hiv infections
administration, oral
aged
evaluation of the transparency committee
insurance, health, reimbursement
guidelines for drug use
HIV-1
anti-retroviral agents
Non-nucleoside Reverse Transcriptase Inhibitor
pyridones
triazoles
pyridones
triazoles
pyridones
triazoles
---
